Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.63 |
| ▸ | CTSB | P07858 | 3/20 | 0.43 |
| ▸ | CTSS | P25774 | 3/20 | 0.43 |
| ▸ | CTSK | P43235 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14595386 | 0.83 | HSD11B1 (0.58) | HSD11B1ALDH1A1KDM4E | |
| SCHEMBL31207070 | 0.81 | CTSB (0.57) | CTSBCTSSCTSKALDH1A1KDM4E | |
| SCHEMBL5605778 | 0.81 | CTSB (0.57) | CTSBCTSSCTSKALDH1A1KDM4E | |
| SCHEMBL20381970 | 0.79 | HSD11B1 (0.96) | HSD11B1ALDH1A1TSHR | |
| SCHEMBL18485325 | 0.78 | HPGD (0.54) | HSD11B1CTSBCTSSCTSKALDH1A1 | |
| SCHEMBL10282316 | 0.77 | HSD11B1 (1.00) | HSD11B1ALDH1A1TSHR | |
| SCHEMBL12632673 | 0.75 | HSD11B1 (0.89) | HSD11B1ALDH1A1KDM4ETSHR | |
| SCHEMBL7903517 | 0.74 | HSD11B1 (0.82) | HSD11B1ALDH1A1KDM4ETSHR | |
| SCHEMBL699775 | 0.74 | HPGD (0.54) | HSD11B1CTSBCTSSCTSKALDH1A1 | |
| SCHEMBL16424491 | 0.74 | HPGD (0.52) | HSD11B1CTSBCTSSCTSKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015766-A1 | Quinoline Derivatives as NK-3 and NK-2 Antagonists | GlaxoSmithKline S.P.A. & Laboratoire | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015766-A1 | Quinoline Derivatives as NK-3 and NK-2 Antagonists | KCNK3, KCNQ3, ACKR3 | HSD11B1 2234/4885CTSB 866/4885CTSS 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.